Vaccine Startup Clover Biopharma Files for Hong Kong IPO

What's new: Clover Biopharmaceuticals, a Chinese biotech startup developing Covid-19 and other vaccines, filed for an initial public offering (IPO) in Hong Kong, joining a raft of vaccine makers seeking financing through a public flotation. Chengdu-based Clover didn't disclose the size of the offering. Goldman Sachs and China International Capital Corporation (CICC) will sponsor the listing. Several Chinese Covid-19 vaccine developers recently signaled attempts to go public, including Beijing Advaccine Biotechnology Co. Ltd. and Suzhou Abogen Biosciences, Caixin learned. The context: Clover has been developing a Covid-19 vaccine based on recombinant protein technology. The company said in February that it…